A better understanding of the mechanisms by which Dyrk1a overexpression results in the neurodevelopmental deficits of DS would provide a rational basis for therapeutics based on targeted inhibition of Dyrk1a to produce enduring improvement of DS phenotypes. Here, DYRK1A is linked to Dravet syndrome.